April 6, 2020

Dr. Stephen Hahn
Commissioner
Office of the Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Dear Commissioner Hahn,

We, the undersigned 80 organizations, urge you to immediately lift the medically unnecessary restrictions on medication abortion that further endanger pregnant people and strain the health care system during the global COVID-19 outbreak. As you may be aware, the United Kingdom Department of Health recently approved home use of both stages of medication abortion to limit the spread of COVID-19. The U.S. FDA should similarly act quickly to protect the health of pregnant people and health care professionals.

Due to the pandemic, one in four Americans are currently under strict shelter-at-home orders to slow the virus’s spread, with more closures expected as the health system copes with a growing caseload. We know that hundreds of thousands of pregnant people will need an abortion during this crisis. For many of these people, access to safe and effective mifepristone could be a lifeline, ensuring they receive prompt abortion care without having to visit a clinic, or even leave their homes.

Yet the FDA mandates that providers must be certified and registered with the drug sponsor to prescribe the drug, and pregnant people must go to a clinic, medical office or hospital to obtain it, rather than through a retail pharmacy — even though the FDA permits patients to wait until they get home to swallow the pill. Solid research and nearly 20 years of clinical experience have demonstrated that these requirements are medically unnecessary.

These requirements have long harmed patients’ health by delaying or blocking access to medication abortion with no countervailing medical benefit. Now, in the midst of a public health emergency, these requirements are further endangering patients and straining the health system. Under the Risk Evaluation and Mitigation Strategies (REMS) and Elements to Assure Safe Use (ETASU) imposed by the FDA on mifepristone, both patients and clinic staff are forced to travel during a pandemic, don protective gear, and increase their exposure to potentially sick individuals — with no corresponding health benefit to justify these serious risks.

Some states have attempted to prohibit clinic-based abortion services altogether by falsely declaring that abortions are “nonessential” procedures and can be delayed during the outbreak. But even in states with robust support for abortion access, clinic services may be curtailed
by nationwide shortages of basic medical supplies and personal protective equipment, such as
gloves and masks.

In every case, requiring pregnant people to travel to providers for services that could be
performed remotely through telehealth consultations in order to receive FDA-approved
medication that could be available at retail pharmacies through pickup or delivery, threatens both
patient and provider.

Sensibly, the FDA has explicitly recognized that enforcement of REMS and ETASU restrictions
during a pandemic “put[s] patients and others at risk for transmission of the coronavirus” and has
suspended its enforcement of critical restrictions imposed on other drugs — even when they have a
far riskier safety profile.

In guidance issued in March, the FDA noted its “critical role in protecting the United States from
threats including emerging infectious diseases” and its commitment “to providing timely
guidance to support response efforts to this pandemic.”

The guidance states:

FDA recognizes that during the COVID-19 PHE [public health emergency], completion
of REMS-required laboratory testing or imaging studies may be difficult because
patients may need to avoid public places and patients suspected of having COVID-19
may be self-isolating and/or subject to quarantine. Under these circumstances,
undergoing laboratory testing or imaging studies in order to obtain a drug subject to a
REMS can put patients and others at risk for transmission of the
coronavirus [emphasis ours].

In light of the FDA’s March guidance and explicit recognition of the dire risks, we urge you to
lift the REMS and ETASU restrictions on mifepristone to ensure that pregnant people have
access to this safe and effective drug even during this national public health crisis. If everyone
who needs a medication abortion can safely access mifepristone through telehealth
appointments and have it shipped to them, then that action alone would alleviate strain on the
health system while protecting patients.

In the absence of this action, the FDA will force pregnant people to pursue alternatives. Some
will turn to overseas pharmacies. While many of us believe that this can be a safe method for
procuring medication abortion, the FDA has argued that doing so “poses an inherent risk to
consumers who purchase those products.” Some pregnant people will use alternative, non-
medical methods of self-managed abortion — as long practiced by women — that can be safe
and effective. But many others will turn to dangerous or unproven methods. Some people who
travel (often over long distances) to pick up mifepristone in a clinic will be exposed to COVID-
19. And, of course, many people will be forced to carry an unwanted pregnancy to term during a
pandemic — with unknown but likely significant risks. In making a risk-benefit analysis
around the REMS and ETASU for mifepristone, the FDA must weigh all of these real-
world considerations.
The FDA is putting the lives of pregnant people at risk. We urge you to take steps now to ensure that mifepristone remains a safe and effective form of abortion care during the crisis.

Thank you for your prompt attention to this urgent public health matter. Please contact Cynthia A. Pearson, Executive Director at the National Women’s Health Network at cpearson@nwhn.org with your response.

Sincerely,

500 Women Scientists
Abortion Care Network
Access Reproductive Care-Southeast
Advocates for Youth
All-Options
American Humanist Association
American Medical Student Association (AMSA)
AMPLIFY GA
Asian & Pacific Islander American Health Forum
Black Women's Health Imperative
California Latinas for Reproductive Justice
Catholics for Choice
Center for American Progress
CHOICES. Memphis Center for Reproductive Health
Civil Liberties and Public Policy
Clearinghouse on Women's Issues
Cobalt
Consumers for Affordable Health Care
Creating a Clinician Corps
DuPont Clinic
Equality California
Equity Forward
EverThrive Illinois
Feminist Majority Foundation
Feminist Women’s Health Center
Florida Access Network
Forward Together Action
Gender Justice
Gender Justice League Seattle
GLMA: Health Professionals Advancing LGBTQ Equality
If/When/How: Lawyering for Reproductive Justice
In Our Own Voice: National Black Women’s Reproductive Justice Agenda
Indiana Religious Coalition for Reproductive Choice
International Campaign for Women's Safe Right to Abortion
International Women's Health Coalition
Ipas
Jacobs Institute of Women's Health
Jane's Due Process
Legal Voice
Medical Students for Choice
NARAL Pro-Choice America
NARAL Pro-Choice Texas
National Abortion Federation
National Advocates for Pregnant Women
National Asian Pacific American Women's Forum
National Center for Lesbian Rights
National Council of Jewish Women
National Health Law Program
National Hispanic Medical Association
National Latina Institute for Reproductive Justice
National Minority Quality Forum
National Network of Abortion Funds
National Organization for Women
National Women’s Health Network
National Working Positive Coalition
New Era Colorado
Our Bodies Ourselves
PAI
Pendergast Consulting
Physicians for Reproductive Health
Population Connection Action Fund
Power to Decide
Progress Florida Education Institute
Public Citizen
Religious Coalition for Reproductive Choice
Reproaction
Reproductive Health Access Project
SIECUS: Sex Ed for Social Change
SisterSong Women of Color Reproductive Justice Collective
Southwest Women's Law Center in Albuquerque, New Mexico
SPARK Reproductive Justice NOW!
Students for Choice
The Women’s Centers
Union of Concerned Scientists
URGE: Unite for Reproductive & Gender Equity
Women First Digital
Women’s Health Specialists
Women Have Options/Ohio
Women’s Law Project, Pennsylvania
WVFREE
CC:
Dr. Janet Woodcock
Director
Center for Drug Evaluation and Research
U.S. Food and Drug Administration